Welcome to our succinct summaries of the most recent healthcare news and insights. Keep yourself informed with our easily digestible updates sourced from medical media and news outlets.

Changes in Incident Schizophrenia Diagnoses Associated With Cannabis Use Disorder After Cannabis Legalization

  • February 2025
  • JAMA Network Open
    • Despite concerns about the potential increase in schizophrenia cases due to cannabis legalization, there is limited evidence on this topic. The objective of this study is to examine changes in the population-attributable risk fraction (PARF) for cannabis use disorder (CUD) associated with schizophrenia following the liberalization of medical cannabis and legalization of nonmedical cannabis in Canada.
    • In this cohort study of individuals aged 14 to 65 years in Ontario, Canada, the proportion of incident cases of schizophrenia associated with CUD nearly tripled during a period of significant cannabis policy liberalization. Further research is needed to fully understand the long-term impact of cannabis policy on the prevalence of psychotic disorders.
    • Abstract
    • Full text

Bioaccumulation of microplastics in decedent human brains

  • February 2025
  • Nature Medicine
    • The increasing global levels of environmental microplastics and nanoplastics (MNPs) have raised concerns regarding human exposure and potential health risks. Various advanced techniques, such as pyrolysis gas chromatography-mass spectrometry, attenuated total reflectance-Fourier transform infrared spectroscopy, and electron microscopy with energy-dispersive spectroscopy, have been employed to accurately detect MNPs in human kidney, liver, and brain tissues. These methods have confirmed the presence of MNPs in these organs, predominantly composed of polyethylene with varying concentrations of other polymers.
    • Interestingly, the analysis revealed that brain tissues contain a higher proportion of polyethylene compared to liver or kidney tissues. Electron microscopy further confirmed the nature of the MNPs found in the brain, which predominantly appear as nanoscale shard-like fragments. This information sheds light on the distribution and composition of MNPs in human organs, highlighting the need for further research to understand the potential implications for human health.
    • Abstract
    • Full text

Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis

  • February 2025
  • New England Journal of Medicine
    • In a phase 2 trial involving patients with lupus nephritis receiving standard therapy, Obinutuzumab, a humanized type II anti-CD20 monoclonal antibody, demonstrated significantly superior renal responses compared to placebo.
    • Among adults with active lupus nephritis, the combination of Obinutuzumab and standard therapy proved to be more effective in achieving a complete renal response than standard therapy alone.
    • Full text

FUTURE-AI: international consensus guideline for trustworthy and deployable artificial intelligence in healthcare

  • February 2025
  • BMJ
    • Despite significant advancements in artificial intelligence (AI) research for healthcare, the implementation and acceptance of AI technologies in clinical practice remain limited. This paper introduces the FUTURE-AI framework, which offers guidance for the creation and utilization of reliable AI tools in healthcare. The FUTURE-AI Consortium was established in 2021 and consists of 117 interdisciplinary experts from 50 countries across all continents, including AI specialists, clinical researchers, biomedical ethicists, and social scientists. Over a two-year period, the FUTURE-AI guideline was developed through consensus based on six core principles—fairness, universality, traceability, usability, robustness, and explainability. To put trustworthy AI into practice in healthcare, a set of 30 best practices were identified, covering technical, clinical, socio ethical, and legal aspects. These recommendations span the entire lifecycle of healthcare AI, from conception, development, and validation to regulation, implementation, and monitoring.
    • Abstract
    • Full text

Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial

  • February 2025
  • The Lancet
    • GLP-1 receptor agonists have shown promising neurotrophic properties in both in-vitro and in-vivo models of Parkinson's disease. Additionally, results from epidemiological studies and small randomized trials have indicated potential benefits for both the risk and progression of Parkinson's disease. Our objective was to determine whether the GLP-1 receptor agonist, exenatide, could effectively slow the progression of Parkinson's disease.
    • Our findings indicate that exenatide is both safe and well-tolerated. However, we did not find any evidence to support exenatide as a disease-modifying treatment for individuals with Parkinson's disease. Further studies utilizing agents that demonstrate improved target engagement, particularly in specific subgroups of patients, are necessary to determine whether there is any validity in utilizing GLP-1 receptor agonists for the treatment of Parkinson's disease.
    • Abstract
    • Full text

Prevalence, Disparities, and Mortality of Cardiovascular-Kidney-Metabolic Syndrome in US Adults, 2011-2018

  • February 2025
  • The American Journal of Medicine
    • The Cardiovascular-Kidney-Metabolic syndrome illustrates the intricate relationship between metabolic risk factors, cardiovascular health, and chronic kidney disease. Disparities in disease prevalence based on demographics, social determinants of health, and mortality rates have not been thoroughly examined.
    • Recent studies have shown that approximately 13% of adults are in advanced stages of the syndrome, with a disproportionate impact on non-Hispanic Black adults and a concerning increase over time. These findings offer valuable insights for developing targeted intervention strategies to address this pressing public health issue.
    • Abstract
    • Full text

Individual and Combined Association Between Healthy Behaviors and All-Cause and Premature Mortality

  • February 2025
  • Mayo Clinic Proceedings
    • The objective of this study is to analyze the impact of individual and combined healthy behaviors on all-cause and premature mortality risk in Mexican adults.
    • Over a span of 22 years, adopting a healthier lifestyle was found to be associated with a decreased risk of all-cause and premature mortality. This risk decreased even further with the addition of each healthy behavior. In order to improve health outcomes and delay mortality, it is imperative to implement law and policy changes that address the root causes of unhealthy behaviors in low- and middle-income countries. Structural conditions should be created to encourage physical activity, and strong social marketing campaigns should be developed to promote the daily consumption of fruits and vegetables.
    • Abstract
    • Full text

Spaced Transcranial Direct Current Stimulation for Major Depression

  • January 2025
  • The American Journal of Psychiatry
    • This study examined the use of spaced transcranial direct current stimulation for treating major depressive disorder, with a specific focus on its feasibility. The protocol proved to be both feasible and safe, with participants tolerating the treatment well. Additionally, the treatment resulted in significant reductions in depressive symptoms. However, further validation is required through a sham-controlled randomized trial.
    • In future trials, the inclusion of neurophysiological measures could provide valuable insights into the biological target engagement of the treatment. This approach may also aid in uncovering underlying mechanisms and discovering potential biomarkers associated with major depressive disorder.
    • Abstract
    • Full text

Sex Differences in Long COVID

  • January 2025
  • JAMA Network Open
    • A significant number of individuals worldwide are experiencing long COVID, also known as post-COVID condition. While other postviral and autoimmune conditions tend to affect more females, it remains uncertain whether the same holds true for long COVID, particularly within different subgroups. The objective of this study is to assess the differences in the likelihood of developing long COVID among adults who have had a SARS-CoV-2 infection.
    • In this prospective cohort study of the NIH RECOVER-Adult cohort, it was found that females were at a higher risk of developing long COVID compared to males. Furthermore, this association was found to be dependent on factors such as age, pregnancy, and menopausal status. These findings underscore the importance of identifying the biological mechanisms that contribute to this specificity in order to facilitate risk stratification, targeted drug development, and improved management of long COVID.
    • Abstract
    • Full text

Thank you for staying updated on the latest healthcare news and insights. Don't miss out on important information - sign up for alerts and stay informed on the latest published guidelines and articles.

Copyright © 2025 Guideline Central, All rights reserved.